Dec
3
11:30 AM11:30

Cambridge Biomedical BTK Occupancy/Immuno Oncology Lunch

Cambridge Biomedical's Scientific Lunch to be held on December 3rd in Cambridge.
While the event is free your RSVP is required. Click on the link below to register or RSVP.

For nearly a decade Cambridge Biomedical has played a role supporting the bioanalytical needs of Immuno Oncology therapies. 

Cambridge Biomedical will discuss our experience in the development and validation of assays for total and free Btk measurement in PBMCs.

Abstract

Bruton's tyrosine kinase (Btk) is a kinase largely expressed in B cells and myeloid cells and it plays an essential role in the B Cell Receptor (BCR) signaling pathway, often involving other members of the Tyrosine Protein Kinase (Tec) family of kinases.

Given the essential role of Btk in the BCR signaling pathway and the normal development and function of B cells, there are several disease indications that have been attributed to abnormal BCR activity. These include autoimmune diseases such as Lupus, MS and RA in which B cells inappropriately break self-tolerance to produce antibodies contributing to the autoimmune disease.  BCR signaling also contributes to several B cell malignancies such as CLL and MCL. New therapies that target BCR signaling are showing remarkable promise in the clinic.

Small molecule covalent inhibitors of Btk such as ibrutinib and acalabrutinib are available for treatment with other similar molecules in development. Measurement of the pharmacodynamic activity of these inhibitors entail an indirect assay to measure unbound or free Btk and comparing it with the total Btk in patients treated with the drug.

Maloy WS.jpg

Maloy M. Mangada, PhD

Dr. Mangada is Associate Director of Scientific Services at Cambridge Biomedical and serves as the lead immunologist directing a team of accomplished scientists in the development and validation of novel high and low complexity   assays.  He has more than 20 years' experience with biomarker assay  development, including 15 years of flow cytometry assay development and validation. Maloy has a PhD in Molecular  Virology,  an MS in Molecular Biology and Biotechnology  and a BS in Applied Physics. He undertook a  Post-Doctoral Research Fellowship, studying T cell immunology at the University of Massachusetts Medical  School.

 

Click on the link below to register or RSVP.

Get more information

Register Now!

I can't make it

If you have any questions please contact:

 Eric Wexler

Cambridge Biomedical

ewexler@cambridgebiomedical.com

View Event →